18Apr 2025
Real-World Insights on Biosimilar Insulin Use and Outcomes

Real-World Insights on Biosimilar Insulin Use and Outcomes

Though insulin's legacy spans over a century, barriers to access and adherence still hinder optimal diabetes care. This review explores real-world evidence (RWE) on biosimilar insulin—its safety, efficacy, cost-effectiveness, and challenges in uptake. Data highlight therapeutic inertia and non-adherence, underscoring the need for fit-for-purpose diabetes registers. Structured RWD integration is vital for evaluating insulin's true impact across diverse diabetes subtypes and improving outcomes globally.

  • #endo-diabetology

Like

Save

Share